{"id":34126,"date":"2024-07-24T15:58:35","date_gmt":"2024-07-24T13:58:35","guid":{"rendered":"https:\/\/phiab.com\/?page_id=34126"},"modified":"2025-08-14T11:37:22","modified_gmt":"2025-08-14T09:37:22","slug":"investor-relations","status":"publish","type":"page","link":"https:\/\/phiab.com\/investor-relations\/","title":{"rendered":"Investor Relations"},"content":{"rendered":"
<\/span>
\n \"Phase\n <\/figure>\n
<\/div>\n

\n Investor Relations<\/strong>\n <\/h1>\n

Welcome to the Investor Relations for Phase Holographic Imaging (PHI)<\/p>\n <\/div>\n <\/div>\n<\/div>\n\n

What’s New<\/h2>\n\n

Press Releases<\/h3>\n
\n
\n \n
\n

Phase Holographic Imaging PHI AB Announces Intent to File for Bankruptcy<\/h2>\n
Phase Holographic Imaging PHI AB (PHI), a pioneer in advanced holographic imaging solutions for life sciences, today announces its intention to file for bankruptcy with the Swedish District Court on January 12, 2026.<\/div><\/a>\n <\/div>\n
\n
1<\/span>2<\/a>3<\/a>…<\/span>160<\/a><\/div><\/a>\n <\/div>\n <\/div>\n <\/div>\n

News featuring PHI<\/h3>\n
\n
\n \n
\n \"Schematic,\n <\/figure>\n
\n

Biostock: PHI comments on expansion into veterinary IVF<\/h2>\n
Phase Holographic Imaging is broadening its focus. The company, which previously operated in regenerative medicine and cell therapy, is now adding the fast-growing field of in vitro fertilization, IVF, for livestock to its pipeline. BioStock contacted CEO Patrik Eschricht to learn more about the decision and what opportunities he sees with the new venture.<\/div><\/a>\n <\/div>\n
\n
1<\/span>2<\/a>3<\/a>…<\/span>41<\/a><\/div><\/a>\n <\/div>\n <\/div>\n <\/div>\n<\/div>\n\n
<\/div>\n\n

About PHI<\/h2>\n\n

Phase Holographic Imaging<\/strong> (PHI) <\/strong>develops and markets its non-invasive time-lapse imaging instruments. The company\u2019s current HoloMonitor\u00ae<\/a> products are globally used for long-term quantitative analysis of living cell cultures, particularly in preclinical research.<\/p>\n\n

Now, PHI is actively focusing on business development. With unique solutions focused on Quantitative Phase Imaging (QPI)<\/a> \u2014 a technology that brings a novel, cell-friendly approach to critical cell quality evaluation, PHI is expanding into the fast-growing regenerative medicine field.<\/p>\n\n

PHI envisions transforming live cell analysis and establishing its QPI technology as a standard for cell quality control<\/a>, making our future cell therapies safe, affordable, and accessible for patients. PHI is based in Lund, Sweden, Boston, MA and Winston-Salem, NC.<\/p>\n\n

\n Learn more about PHI<\/a>\n <\/div>\n
\n Key Figures<\/a>\n <\/div>\n
\n Why invest in PHI?<\/a>\n <\/div>\n<\/div>\n\n
\n